Is NanJing Pharmaceutical (SHSE:600713) Using Too Much Debt?

Simply Wall St54minutes ago

nanjing pharmaceutical (600713.SH) has been approved to register 6 billion yuan of ultra-short-term financing bonds.

Nanjing Pharmaceutical(600713.SH) announced that the company received a notice from Bank of China on October 30, 2024...

Zhitong FinanceOct 31 03:47 ET

Nanjing Pharmaceutical: Full text of Nanjing Pharmaceutical\'s 2024 third quarter report

SZSIOct 30 12:00 ET · Announcements

Full text of Nanjing Pharmaceutical\'s 2024 third quarter report

SZSIOct 30 12:00 ET · Announcements

Nanjing Pharmaceutical (600713.SH) released its performance for the first three quarters, with net income of 0.442 billion yuan, a 0.36% year-on-year increase.

nanjing pharmaceutical (600713.SH) released the third quarter report for 2024, with revenue for the first three quarters reaching 40...

Zhitong FinanceOct 30 04:02 ET

Nanjing Pharmaceutical (600713.SH): The net income for the first three quarters was 0.442 billion yuan, a year-on-year increase of 0.36%.

Gelonghui October 30th | Nanjing Pharmaceutical (600713.SH) announced the third quarter report of 2024, with the company's revenue in the first three quarters of 40.938 billion yuan, a year-on-year increase of 0.97%; net income attributable to shareholders of the listed company was 0.442 billion yuan, a year-on-year increase of 0.36%; basic earnings per share was 0.34 yuan.

Gelonghui FinanceOct 30 03:40 ET